

































nResuscitation 92 (2015) 70–76
Contents lists available at ScienceDirect
Resuscitation
journa l ho me  pa g e: www. els evier .com/ locate / resusc i ta t ion
linical  paper
anaging  cardiac  arrest  with  refractory  ventricular  ﬁbrillation  in  the
mergency  department:  Conventional  cardiopulmonary  resuscitation
ersus  extracorporeal  cardiopulmonary  resuscitation
u-Yuan  Siaoa,b,1, Chun-Chieh  Chiua,1, Chun-Wen  Chiua, Ying-Chen  Chenc, Yao-Li  Chenc,
ung-Kun  Hsiehc,  Chien-Hui  Leec,  Chang-Te  Wua,  Chu-Chung  Choua, Hsu-Heng  Yend,e,∗
Department of Emergency Medicine, Changhua Christian Hospital, Changhua, Taiwan
Department of Critical Care Medicine, Changhua Christian Hospital, Changhua, Taiwan
Department of Cardiovascular Surgery, Changhua Christian Hospital, Changhua, Taiwan
Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
College of Medicine, Chung-Shan Medical University, Taichung, Taiwan
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 7 January 2015
eceived in revised form 7 April 2015











a  b  s  t  r  a  c  t
Aim:  Refractory  ventricular  ﬁbrillation,  resistant  to  conventional  cardiopulmonary  resuscitation  (CPR),  is
a life  threatening  rhythm  encountered  in the  emergency  department.  Although  previous  reports  suggest
the  use  of extracorporeal  CPR  can improve  the clinical  outcomes  in patients  with  prolonged  cardiac
arrest,  the  effectiveness  of this  novel  strategy  for refractory  ventricular  ﬁbrillation  is  not  known.  We
aimed  to compare  the  clinical  outcomes  of patients  with  refractory  ventricular  ﬁbrillation  managed  with
conventional  CPR  or extracorporeal  CPR  in our institution.
Method:  This is a  retrospective  chart  review  study  from  an  emergency  department  in a  tertiary  referral
medical  center.  We  identiﬁed  209  patients  presenting  with  cardiac  arrest  due  to  ventricular  ﬁbrillation
between  September  2011  and  September  2013.  Of these,  60 patients  were  enrolled  with  ventricular
ﬁbrillation  refractory  to resuscitation  for more  than  10 min.  The  clinical  outcome  of  patients  with  ven-
tricular ﬁbrillation  received  either  conventional  CPR,  including  deﬁbrillation,  chest  compression,  and
resuscitative  medication  (C-CPR,  n  =  40)  or CPR  plus  extracorporeal  CPR  (E-CPR,  n = 20)  were  compared.
Results:  The  overall  survival  rate  was  35%,  and  18.3%  of  patients  were  discharged  with  good  neuro-
logical  function.  The  mean  duration  of CPR  was  longer  in  the  E-CPR  group  than  in  the C-CPR  group
(69.90 ± 49.6  min  vs 34.3  ± 17.7 min,  p =  0.0001).  Patients  receiving  E-CPR  had  signiﬁcantly  higher  rates
of  sustained  return  of  spontaneous  circulation  (95.0%  vs  47.5%,  p  =  0.0009),  and  good  neurological  func-
tion  at  discharge  (40.0%  vs  7.5%,  p = 0.0067).  The  survival  rate  in the  E-CPR  group  was  higher  (50%  vs
27.5%,  p  =  0.1512)  at discharge  and  (50%  vs  20%, p = 0. 0998)  at 1  year  after  discharge.
Conclusions:  The  management  of  refractory  ventricular  ﬁbrillation  in  the  emergency  department  remains
challenging,  as  evidenced  by an  overall  survival  rate  of 35%  in  this  study.  Patients  with  refractory  ven-
ing  E
an thtricular  ﬁbrillation  receiv
neurological  outcomes  th©  2015  The  Authors.  Pu
Abbreviations: C-CPR, conventional cardiopulmonary resuscitation; E-CPR,
xtracorporeal cardiopulmonary resuscitation; OHCA, out-of-hospital cardiac
rrest; IHCA, in-hospital cardiac arrest; ROSC, return of spontaneous circulation;
OSB, return of spontaneous beating; CPC, cerebral performance category; CPR,
ardiopulmonary resuscitation; AHA, American Heart Association.
 A  Spanish translated version of the abstract of this article appears as Appendix
n  the ﬁnal online version at http://dx.doi.org/10.1016/j.resuscitation.2015.04.016.
∗ Corresponding author at: Department of Internal Medicine, Changhua Christian
ospital, Changhua, Taiwan.
E-mail address: 91646@cch.org.tw (H.-H. Yen).
1 These two authors contributed equally to this manuscript.
ttp://dx.doi.org/10.1016/j.resuscitation.2015.04.016
300-9572/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).-CPR  had  a trend  toward  higher  survival  rates  and  signiﬁcantly  improved
ose  receiving  C-CPR.
blished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cardiac arrest that is refractory to cardiopulmonary resusci-
tation (CPR) carries a high mortality rate, especially when the
duration of resuscitation persists beyond 10 min.1 The effect of
conventional CPR (C-CPR) falls rapidly, with decreased survival
beyond the ﬁrst 10–15 min and only 2% patients achieve a favorable
neurological outcome.2 Although patients with cardiac arrest due
to ventricular ﬁbrillation tend to respond more favorably to C-CPR
compared with other etiologies of cardiac arrest,1,3 the clinical






















































the C-CPR group at discharge (50% vs 27.5%) and one year after dis-F.-Y. Siao et al. / Resu
utcome is poor if they fail to respond within the ﬁrst 10 min.4,5
ndeed, the reported survival rate is 20.4% in this scenario, with
nly 5.6% of patients regaining good neurological outcomes in out
f hospital arrest.6
A previous study suggests that using extracorporeal membrane
xygenation (ECMO) in extracorporeal CPR (E-CPR) can improve
he clinical outcomes in patients with prolonged cardiac arrest
eyond 10 min.4 However, the cost of ECMO is high and the patient
haracteristics that are likely to gain most from ECMO have not
een established.7,8 Ventricular ﬁbrillation is considered refrac-
ory if no return of spontaneous circulation (ROSC) occurs after
-CPR for more than 10 min. Few case reports describe the use
f ECMO in patients with prolonged cardiac arrest due to refrac-
ory ventricular ﬁbrillation, particularly with excellent clinical
utcomes.9–13 Whether or not this unconventional strategy can
e applied to the management of refractory ventricular ﬁbrilla-
ion in the emergency department and improve patient outcomes is
nclear.
In this study, we aimed to study the clinical outcomes of patients
ith refractory ventricular ﬁbrillation. Speciﬁcally, we assessed the
ffects of C-CPR versus E-CPR in this patient group.
. Patients and methods
A retrospective medical chart review at a medical center was
erformed between September 2011 and September 2013. The
tudy was approved by our Institutional Review Board. We  enrolled
atients who fulﬁlled the following criteria: (1) age 18–75 years;
2) cardiac arrest with initial ventricular ﬁbrillation and C-CPR
nitiated within 5 min  (no ﬂow duration <5 min); (3) refractory
entricular ﬁbrillation deﬁned as ventricular ﬁbrillation resis-
ant to at least three deﬁbrillations, 3 mg  of epinephrine, 300 mg
f amiodarone, and no ROSC achieved after CPR for more than
0 min.14
Patients were excluded if they had (1) severe head trauma or
evere acute active bleeding; (2) severe sepsis; (3) ventricular ﬁbril-
ation that developed during resuscitation for initial asystole or
ulseless electrical activity; (4) terminal stage of malignancy; and
5) any history of severe neurological deﬁcits (including dementia,
ntracranial hemorrhage, or ischemic stroke and bedridden state).
.1. Assessment of the resuscitation process and clinical outcome
We  retrospectively reviewed the number of deﬁbrillation
ttempts and drugs used, as well as the duration of resuscitation.
ustained ROSC was deﬁned as more than 20 min  of sponta-
eous circulation without recurrence of cardiac arrest. The CPR
rocess was stopped when sustained ROSC was achieved. The deci-
ion to discontinue CPR was made if there was  no ROSC after
0 min  resuscitation. Neurological outcome was  evaluated using
he Glasgow–Pittsburgh cerebral performance category (CPC) scale.
ood neurological outcome was deﬁned as a CPC score of 1 or 2,
oor cerebral function as a CPC score of 3 or 4, and brain death
s a CPC of 5. Patients were followed to either discharge from the
ospital or death.
.2. The ECMO system and intervention
In our hospital, E-CPR was permitted as an option in pro-
onged CPR, according to the judgment of the attending physician.
he ECMO system comprised a Bio-Pump® centrifugal blood
ump (Medtronic Inc., Anaheim, CA), a Maxima Plus PRF hollow
embrane oxygenator with an integral heat exchanger, and a
eparin-bonded Carmeda Bioactive Surface circuit. The pump ﬂowon 92 (2015) 70–76 71
was controlled to maintain a minimum ﬂow of 2.0 L min−1. The
activated clotting time was  maintained at 180–220 s with heparin.
We performed E-CPR via femoral cannulation in the emergency
department. Once the patient achieved sustained ROSB (return of
spontaneous beating) after ECMO, they were transferred to inten-
sive care. Therapeutic hypothermia is considered when the patients
remain comatose after ROSC (C-CPR group) or ROSB (E-CPR group)
and decided by the attending physician of the intensive care unit.
Therapeutic hypothermia was  provided as follows: the patient
was cooled to 33 ◦C for 24 h and rewarmed at 0.5 ◦C every 4 h till
tympanic temperature reached 37 ◦C. Emergency coronary angiog-
raphy was  performed by cardiologist if acute myocardial infarction
was suspected.
2.3. Statistical analyses
Continuous variables were compared using Student’s t-test or
Mann–Whitney U-test as appropriate. Categorical variables were
evaluated using the 2 test. Logistic regression modeling was used
to evaluate factors associated with clinical outcome. Differences
between the two groups were considered signiﬁcant when the
P-value was  <0.05. Statistical analyses were performed using Med-
Calc software version 11.5 (MedCalc Software bvba, Broekstraat 52,
9030 Mariakerke, Belgium).
3. Results
3.1. Patient characteristics of refractory ventricular ﬁbrillation
During the study period, we  identiﬁed 209 patients with cardiac
arrest due to ventricular ﬁbrillation. Of these, 60 patients who had
initial ventricular ﬁbrillation that fulﬁlled the inclusion and exclu-
sion criteria were enrolled (Fig. 1). The mean age was 58.37 years,
with male predominance. Forty-one of the cases had out of hospital
cardiac arrest (OHCA). The leading cause of cardiac arrest was  acute
myocardial infarction (46.67%).
The resuscitation process was illustrated in Fig. 2. The mean
duration of resuscitation was 46.22 min, with a mean of 7.65 deﬁb-
rillations performed. ECMO support was  provided for 20 (33.33%)
patients and successful cannulation achieved in 19 patients. 18
(30%) patients received therapeutic hypothermia. In our study,
38 (63.33%) patients achieved sustained ROSC/ROSB and all were
transferred to intensive care. In total, 21 (35%) patients survived
to discharged; however, only 11 (18.33%) had good neurological
function at discharge.
3.2. Comparison of the C-CPR and E-CPR groups
We divided patients into C-CPR and E-CPR groups for further
comparison (Table 1). Age, sex, amiodarone dose, co-morbidity dis-
ease, cause of cardiac arrest, location of cardiac arrest, serum lactate
levels, and therapeutic hypothermia were similar in both groups.
In the E-CPR group, patients had longer duration of resuscitation
(E-CPR vs C-CPR: 69.90 min  vs 34.38 min, p = 0.0001), more deﬁ-
brillation attempts (E-CPR vs C-CPR: 9.72 vs 6.56, p = 0.0001), and
more doses of epinephrine (E-CPR vs C-CPR: 11.17 mg  vs 8.29 mg,
p = 0.032). Patients in the E-CPR group also had signiﬁcantly higher
rates of sustained ROSC and survival to intensive care when com-
pared with the C-CPR group (95% vs 47.5%, p = 0.0009). The overall
survival rate was  also higher in the E-CPR group compared withcharge (50% vs 20%), although this was not statistically signiﬁcant.
However, the rate of good neurological function was signiﬁcantly
higher at discharge in the E-CPR group than in the C-CPR group (40%
vs 7.5%, p = 0.0067).















iFig. 1. Diagram for patie
.3. Comparison of the E-CPR subgroup
We  divided E-CPR patients into subgroups (survivor vs non-
urvivor) for further comparison with the time course of E-CPR
ere provided in Table 2. Age, sex, resuscitation drug dose, location
f cardiac arrest, CPR to ECMO duration and ECMO set-up time were
imilar. In the survivor group, patients had shorter no-ﬂow dura-
ion, lower lactate level and higher proportion of acute myocardiac
nfarction (80%), although these were not statistically signiﬁcant.
.4. Factor analysis for clinical outcome
Clinical factors including age, sex, CPR duration, deﬁbrillation
pisodes, ECMO use, and hypothermia use were further analyzed
ith logistic regression to determine the factors that predicted thewo main clinical outcomes: survival to discharge (Table 3) and
ood neurological function at discharge (Table 4). No signiﬁcant
linical factor was able to predict patient survival to discharge
n refractory ventricular ﬁbrillation. However, the ECMO supportnagement and outcome.
(odds ratio: 25.44, 95% conﬁdence interval: 2.6795–241.4981) sig-
niﬁcantly predicted good neurological function at discharge.
4. Discussion
Prolonged cardiac arrest due to refractory ventricular ﬁbril-
lation represents an extremely critical status that can result in
poor outcomes through C-CPR alone. Our results demonstrate that
resuscitation with ECMO support (E-CPR) might produce outcomes
that are more favorable for patients.
Overall, the survival rate was 35% in our study at discharge,
with good neurological outcomes occurring in 18.3% of all patients
resuscitated for refractory ventricular ﬁbrillation at discharge. The
results in our C-CPR group, with a survival rate of 27.5% and a good
neurological outcome rate of 7.5%, were comparable to those in the
existing literature.15–17 Although the survival rate of ventricular
ﬁbrillation following C-CPR improved from 15.4% in 1998 to 20.4%
in 2006, neurological outcomes following refractory ventricular
ﬁbrillation have remained largely unchanged (from 7.7% to 5.6%)
over the past decade.6 In contrast, we demonstrated particularly
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Fig. 2. Diagram for the resuscitation process.
Table 1
Patient data and outcomes in conventional cardiopulmonary resuscitation and extracorporeal cardiopulmonary resuscitation subgroups.
C-CPR E-CPR All cases p*
Case no (n) 40 20 60
Age,  year, mean (SD) 60.28 (11.23) 54.55 (11.94) 58.37 (11.70) 0.074
Sex  (M/F) 28/12 18/2 36/14 0.178
OHCA/IHCA 30/10 11/9 41/19 0.2021
Resuscitation drug usage
Amiodarone, mg,  mean (SD) 497.03 (205.23) 583.33 (261.78) 526.90 (227.63) 0.1963
Epinephrine, mg,  mean (SD) 8.29 (4.52) 11.17 (4.37) 9.29 (4.63) 0.032
Duration of resuscitation, min  (SD) 34.38 (17.71) 69.90 (49.60) 46.22 (35.84) 0.0001
Episodes of deﬁbrillation, times, mean (SD) 6.56 (3.66) 9.72 (4.20) 7.65 (4.12) 0.0069
Lactate level, IU/ml, mean (SD) 8.25 (5.54) 8.90 (2.29) 8.63(3.92) 0.6580
Comorbidity disease
Coronary artery disease, n (%) 18 (45%) 13 (65%) 31 (51.7%) 0.2351
Hypertension, n (%) 17 (42.5%) 13 (65%) 30 (50%) 0.1709
Diabetes mellitus, n (%) 17 (42.5%) 8 (40%) 25 (41.67%) 0.9262
Pulmonary disease, n (%) 6 (15%) 4 (20%) 10 (16.67) 0.9025
Renal  insufﬁciency, n (%) 11 (27.5%) 4 (20%) 15 (25%) 0.7518
Chronic liver disease, n (%) 6 (15.0%) 2 (10.0%) 8 (13.3%) 0.8932
Hyperlipidemia 9 (22.5%) 7 (35.0%) 16 (26.67%) 0.4700
Cause  of cardiac arrest 0.2084
Acute  myocardial infarction 16 (40%) 12 (60%) 28 (46.67%)
Cardiomyopathy 4 (10%) 2 (10%) 6 (10%)
Suspected myocarditis 0 (0%) 2 (10%) 2 (3.3%)
Valvular heart disease 1 (2.5%) 0 (0%) 1 (1.7%)
Respiratory disease 6 (15%) 2 (10%) 8 (13.3%)
Electrolyte/toxin 6 (15%) 1 (5%) 7 (11.7%)
Others 7 (17.5%) 1 (5%) 8 (13.3%)
Sustained ROSC/ROSB, n (%) 19 (47.5%) 19 (95.0%) 38 (63.3%) 0.0009
Subsequent intervention
PCI 16 (40%) 12 (60%) 28 (46.67%) 0.2343
IABP  10 (25%) 10 (50%) 20 (33.3%) 0.0998
Therapeutic hypothermia, n (%) 9 (22.5%) 9 (45%) 18 (30%) 0.3136
Survival to discharge, n (%) 11 (27.5%) 10 (50%) 21 (35%) 0.1512
Good  neurological function at discharge, n (%) 3 (7.5%) 8 (40%) 11 (18.33%) 0.0067
1  year survival, n (%) 10 (25%) 10 (50%) 20 (33.3%) 0.0998
Good  neurological function (CPC 1 or 2) at 1 year, n (%) 3 (7.5%) 8 (40%) 11 (18.33%) 0.0067
CPR, cardiopulmonary resuscitation (C-CPR = conventional CPR, E-CPR = CPR with ECMO support); ROSC, return of spontaneous circulation; ROSB, return of spontaneous
beating; ECMO, extracorporeal membrane oxygenation; SD, standard deviation; ICU, intensive care unit; CPC, cerebral performance category; IHCA, in-hospital cardiac
arrest; OHCA, out-of-hospital cardiac arrest.
* Comparison between the C-CPR and E-CPR groups.
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Table 2
Patient data and outcomes in extracorporeal cardiopulmonary resuscitation subgroups (survivor vs non-survivor).
Survivor Non-survivor p
Case 10 10
Sex  (M/F) 8/2 10/0 0.4561
Age,  year, mean (SD) 55.9 (12.56) 53.20 (11.80) 0.626
IHCA/OHCA 6/4 3/7 0.3687
Resuscitation drug usage
Amiodarone, mg,  mean (SD) 583.33 (355.32) 583.33 (139.19) 1.0
Ephiephrine, mg,  mean (SD) 10.89 (3.89) 11.44 (5.03) 0.796
Cause  of cardiac arrest
Acute myocardial infarction (n, %) 8 (80%) 4 (40%) 0.1709
No-ﬂow duration (min, collapse to initial CPR) 1–4 1–5 0.07
CPR  to ECMO duration, min, mean (SD) 56.5 (62.02) 41.5 (25.73) 0.489
Median, min 37.5 31 0.9698
Range, min  15–226 17–75
ECMO set-up time, min, mean (SD) 18.80 (2.20) 17.70 (3.95) 0.451
ECMO duration, h, mean (SD) 77.90 (27.45) 81.44 (42.81) 0.207
.97) 







































tained ROSC/ROSB allowed emergency coronary angiography andLactate level, IU/ml, mean (SD) 8.04 (1
PR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation
rrest.
ood neurological outcomes (40%) in those receiving E-CPR, which
uggests that the addition of ECMO support may  be a helpful tool
n patients with refractory ventricular ﬁbrillation.
The management of prolonged cardiac arrest due to refractory
entricular ﬁbrillation is a clinical challenge. Among the vari-
us etiologies of cardiac arrest, when ventricular ﬁbrillation is
he initial rhythm, the outcome is relatively favorable. Following
he increased use of automated external deﬁbrillators in pub-
ic, early deﬁbrillation has improved the survival rate from this
rrhythmia.18 However, management becomes challenging when
he rhythm becomes “shock-resistant” in the emergency depart-
ent, and there are no current guidelines for its management.14
 few case reports have illustrated successful beta-blocker use in
atients with refractory ventricular ﬁbrillation.19 Hassan et al.,20
ave tried magnesium sulfate, but showed similar survival rates
f 4% compared to 2% for conventional therapy. Harayama et al.,21
eported 28% and 18% rates of survival to discharge with nifekalant
nd amiodarone, respectively. However, neither of these reports
howed survival advantages or improved neurological outcomes
ver conventional therapy. Recently, case reports have indicated
hat ECMO, as an adjunct to cardiac resuscitation, can produce good
utcomes for patients with refractory ventricular ﬁbrillation.9–13
e  previously reported a successful case of refractory ventricular
brillation resuscitated with ECMO after 250 min  of C-CPR.11 How-
ver, the use of ECMO for prolonged cardiac arrest with refractory
brillation in the emergency department is limited to case reports.
he current study shows the favorable neurological outcomes in
his setting and our ﬁnding is consistent with the recent published
HEER trial (Refractory cardiac arrest treated with mechanical
PR, hypothermia, ECMO and early reperfusion)22 with a protocol
ncluding E-CPR instituted by critical care physicians for refractory
ardiac arrest (including mechanical CPR, therapeutic hypother-
ia  and ECMO) showing a 54% survival rate with intact neurologic
utcome.
able 3
ogistic regression analysis of factors associated with survival to discharge.
Variable Odds ratio 95% CI
Age (years) 1.0224 0.9642–1.0841
CPR duration (min) 0.9658 0.9228–1.0108
Use of ECMO 4.1016 0.7914–21.2577
Deﬁbrillation (times) 1.0105 0.7925–1.2884
Female gender 0.3738 0.0624–2.2410
Use of therapeutic hypothermia 3.3651 0.8936–12.6715
esults are odds ratios and 95% conﬁdence intervals. ECMO, extracorporeal mem-
rane oxygenation.9.97 (2.30) 0.07
standard deviation; IHCA, in-hospital cardiac arrest; OHCA, out-of-hospital cardiac
In the 2010 advanced cardiac life support (ACLS) guidelines, it
is noted that there is insufﬁcient evidence to recommend the rou-
tine use of E-CPR for patients in cardiac arrest.23 A previous study
from Taiwan found that E-CPR resulted in a higher survival rate
compared with C-CPR (19.6% vs 13.0%), but that it had similar neu-
rological outcomes following in-hospital cardiac arrest.15 A study
of witnessed out-of-hospital cardiac arrest in Japan reported over-
all survival of 29.2% and 8.3% for E-CPR and C-CPR, respectively.24
Although ECMO support could promote coronary blood ﬂow and
increase the rate of ROSC,25 its use is restricted to the cost and the
limited impact on neurological outcome. Therefore, the potential
sub-group that can beneﬁt from E-CPR is poorly characterized.7,8
In this study, we  aimed to target a speciﬁc group of patients
with witnessed cardiac arrest due to refractory ventricular ﬁbrilla-
tion. All patients received repeat deﬁbrillation attempts and high
doses of epinephrine and amiodarone, and the overall survival
rate of 35% was  higher than that previously reported.6 The study
showed a trend toward a higher rate of survival in the E-CPR group
compared with the C-CPR group (50% vs 27.5%, p = 0.1512). We
also found a signiﬁcantly higher rate of sustained ROSC/ROSB in
the E-CPR group compared with that in the C-CPR group, despite
the higher frequency of deﬁbrillation and the higher doses of
epinephrine in the E-CPR group. We believe that patients in the
E-CPR group with a high rate of sustained ROSC/ROSB resulted
from the use of ECMO support. During resuscitation, sustained
ROSC/ROSB provides adequate time for subsequent intervention
and contributes to survival to discharge and good neurological
function. For example, in a case of acute coronary syndrome
with refractory ventricular ﬁbrillation,10 the achievement of sus-prompt percutaneous coronary intervention. In another case of
hyperkalemia with refractory ventricular ﬁbrillation,9 subsequent
dialysis was not possible without ECMO support. Therefore, E-CPR
Table 4
Logistic regression analysis of factors associated with good neurological function at
discharge.
Variable Odds ratio 95% CI
Age (years) 1.0621 0.9757–1.1561
CPR duration (min) 0.9695 0.9194–1.0223
Use of ECMO 25.4382 2.6795–241.4981
Deﬁbrillation (times) 0.9907 0.7366–1.3325
Female gender 1.2560 0.1190–13.2589
Use of therapeutic hypothermia 1.1057 0.1870–6.5362

































































cF.-Y. Siao et al. / Resu
ppears suitable for the management of cardiac arrest due to refrac-
ory ventricular ﬁbrillation.
Generally, the longer the duration of CPR, the more severe are
he complications. These include gastrointestinal bleeding, acute
enal injury, multiple organ failure, and brain death,26 leading
o greater mortality. Given that prolonged CPR results in a sig-
iﬁcant elevation in lactate levels, the high level of lactate may
e a chemical marker of poor perfusion. For example, a previous
eport indicated that lactate levels were associated with neurolog-
cal defects in patients resuscitated from ventricular ﬁbrillation.27
n addition, a recent animal study regarding ventricular ﬁbrillation
emonstrated a signiﬁcant improvement in survival after 15 min
f normothermic cardiac arrest with the use of an ECMO-based
ife support system to optimize blood pressure and ﬂow.28 These
esults support our hypothesis that using ECMO to control circu-
atory pressure and ﬂow after arrest may  be superior to C-CPR.
espite the longer resuscitation times for E-CPR (69.90 min  vs
4.38 min  for E-CPR vs C-CPR; p = 0.0001) in our patients, we found
o differences in the blood lactate levels (8.90 vs 8.25 mmol  L−1 for
-CPR vs C-CPR, p = 0.6580) between the two groups, suggesting
hat ECMO may  have helped to maintain tissue perfusion despite
he prolonged resuscitation times.
In addition, a major complication of prolonged cardiac arrest
s brain damage. Previous reports have indicated that therapeu-
ic hypothermia with body temperature 32–34 ◦C for 12–24 h
an improve neurological outcomes and decrease mortality in
omatose patients following a cardiac arrest.29 Although thera-
eutic hypothermia was considered when the patients remain
omatose after ROSC in the 2010 AHA guideline, the use of ther-
peutic hypothermia was currently not covered by the health
nsurance in Taiwan.30 Thus, this limits the universal use of such
trategy in our intensive care unit. In our study, good neurologi-
al outcomes were more common in the E-CPR group compared
ith the C-CPR group (40% vs 7.5%, p = 0.0067). Despite the E-
PR group received more therapeutic hypothermia (45%) than the
-CPR group (22.5%), the use of ECMO was the only signiﬁcant
actor associated with good neurological function in this study.
he recent Target Temperature Management trial (TTM-trial) ran-
omized controlled trial involving 939 patients after cardiac arrest
ound therapeutic hypothermia with a targeted temperature of
3 ◦C did not confer beneﬁt as compared with a targeted temper-
ture of 36 ◦C.31 In fact, the body temperature usually fell below
6 ◦C after ROCS due to prolonged resuscitation in our observation.
nly four patients (two in E-CPR group and two in C-CPR group)
ith a body temperature more than 36 ◦C did not receive thera-
eutic hypothermia in our study. This may  explain why the beneﬁt
rom therapeutic hypothermia is not found in this study. Our study
uggests that the timely use of ECMO helped to maintain perfusion
o vital organs such as the myocardium and the brain during the
esuscitation process, which contributed to improved neurological
utcomes.32
This study has several limitations, notably that it was a retro-
pective observational study rather than a randomized controlled
rial. It is not possible to randomize our patients to E-CPR or
-CPR in clinical practice. Indeed, although we provide infor-
ative data comparing E-CPR with C-CPR, the former is not a
tandard emergency department therapy. Because E-CPR is not rou-
inely available, our ﬁndings cannot be generalized to emergency
epartments where ECMO is unavailable. Even in our department,
linicians may  opt to use ECMO in younger patients with underlying
oronary artery disease. While we concede that this may  have led
o selection bias and unduly favorable outcomes, we  also observe
hat the E-CPR group had unfavorable features with prolonged CPR
uration. A prolonged CPR times is known to decrease the survival
nd good neurological function rates. In addition, hypothermia is
onsidered a useful therapeutic approach in unconscious patients
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after ROSC but the optimal use (i.e. method, timing, target tem-
perature, duration, indication) of therapeutic hypothermia is not
standardized23,31 and is not routinely used in our daily practice. Our
ﬁnding that ECMO rather than hypothermia contributed to intact
neurological recovery is interesting and a large prospective study
will be needed to explore their roles in refractory ventricular ﬁbril-
lation. Finally, candidates who  gain the most beneﬁt from ECMO
during cardiac arrest remain unclear, which is a critical issue given
the cost of ECMO. Although our study is retrospective and limited
the use of ECMO to speciﬁc cases, our ﬁnding suggest a favorable
survival outcome using ECMO. Therefore, we believe that future
studies on ECMO for this indication are warranted.
5. Conclusions
The management of refractory ventricular ﬁbrillation in the
emergency department is challenging, conﬁrmed by an overall sur-
vival rate of 35% in this study. Patients with refractory ventricular
ﬁbrillation receiving E-CPR tended to have higher survival rates
and signiﬁcantly improved neurological outcomes when compared
with those receiving C-CPR.
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